Skip to main content
JJOS Demo Journals
HomeJournalsCascadia Journal of Biomedical ResearchVolume 14, Issue 110.58302/xenkhn67
Cascadia Journal of Biomedical Research
Review

Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma: a supplementary report

Olivier Dubois1* (unauthenticated), Sanjay Sharma2, Margot Dubois3

1Department of Biomedical Sciences, Pacific Rim University, Australia

2School of Public Health, Meridian National University, Singapore

3School of Physics, Federal University of Rio Verde, Brazil

* Correspondence: olivier.dubois@pacificrim.example

Cascadia J. Biomed. Res. 2022, 14(1), e8501; https://doi.org/10.58302/xenkhn67

Abstract

Renal cell carcinoma (RCC) is a highly vascularized and immunogenic malignancy with a complex tumor microenvironment (TME) that shapes disease progression and therapeutic resistance. Despite advances in immune checkpoint inhibitors (ICIs) and targeted therapies, clinical responses remain heterogeneous, underscoring the need for a deeper understanding of RCC immunobiology. This review comprehensively examines the immunosuppressive TME of RCC, emphasizing the roles of cytotoxic and immunosuppressive immune cells, carcinoma-associated fibroblasts (CAFs), abnormal vasculature, and extracellular matrix (ECM) remodeling in fostering immune evasion. This review summarized emerging biomarkers—including PD-L1 expression, tumor mutational burden (TMB), gene mutations, and immune-based subtypes—that may predict ICI response. Furthermore, we evaluate current immunotherapeutic strategies, such as ICIs, combination therapies, and novel approaches targeting immunosuppressive cells and metabolic pathways. While combination therapies have improved outcomes, challenges like toxicity and resistance persist, necessitating biomarker-driven patient stratification and optimized treatment sequencing. Future directions should focus on deciphering TME heterogeneity and developing precision immunotherapy strategies to enhance clinical efficacy in RCC.

Keywords:renal cell carcinomatumor microenvironmentimmunosuppressive cellsbiomarkersimmunotherapycombined targeted/immunotherapy

1 Introduction

Renal cell carcinoma (RCC), a lethal genitourinary tumor originating from renal tubular epithelial cells, ranks among the top fifteen cancers globally (1). It exhibits a 30–40% mortality rate, with higher prevalence in males. Risk factors include obesity, hypertension, smoking, and chronic kidney disease (2). Early-stage RCC is often asymptomatic; however, advances in CT, MRI, PET-CT, and genetic testing have improved detection, with over 60% of cases diagnosed incidentally. While early-stage patients benefit from surgery, 30% present with metastasis at diagnosis. Post-surgical recurrence occurs in 30–40% of advanced cases, and 50% develop distant metastases, leading to poor prognosis (3, 4).

Clear cell RCC (ccRCC) is the most common subtype and dominates metastatic RCC (mRCC) pathology. Due to RCC’s resistance to radiation/chemotherapy, targeted therapy has been the first-line treatment, though drug resistance remains inevitable (5, 6). Immune checkpoint inhibitors (ICI) show efficacy, but only a subset of patients show response, potentially due to the immunosuppressive tumor microenvironment (TME) (7, 8). RCC TME features extensive immune infiltration, vascularity, and fibrosis, enabling immunotherapy but also influencing treatment resistance via complex interactions (9, 10). Recent therapeutic strategies for advanced RCC have evolved from targeted therapy to combined targeted/immunotherapy approaches (11, 12). This review discusses RCC TME crosstalk, clinical immunotherapy progress, and emerging TME-based biomarkers/therapeutic targets.

2 Characteristics of the TME in renal cell carcinoma

2.1 Cytotoxic immune cells

CD8+ T cells infiltrating the RCC TME frequently exhibit high expression of inhibitory checkpoint receptors—including programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3)—alongside low levels of proliferative markers such as Ki-67, suggesting a state of dysfunction and exhaustion (13, 14). In a meta-analysis of 124 studies, Fridman et al. (15) reported that, unlike in most solid tumors, CD8+ T cell infiltration in RCC correlates with poorer prognosis. While the underlying mechanism remains unclear, one hypothesis is that prolonged exposure to immunosuppressive cells and factors within the RCC TME impairs CD8+ T cells’ ability to recognize antigens, proliferate, and secrete interleukin-2 (IL-2), ultimately abrogating their cytotoxic functions (16). Recent mechanistic studies indicate that chronic antigen stimulation activates NFAT in the absence of AP−1, which drives the transcription of TOX and WNK1, committing CD8+ T cells to an exhausted phenotype (17–19). In RCC, tumor-derived PD-L1 binds PD-1 on CD8+ T cells, recruiting SLC11A1 and inactivating ZAP70 and PI3K/AKT signaling, while CTLA−4 competes for B7 ligands on APCs to prevent costimulation (20–24). Additionally, Tim−3–Galectin−9 interactions promote Batf expression, further enforcing the exhausted transcriptional program (25). These events converge to reduce granzyme B production, IFN-γ secretion, and proliferative capacity. Single-cell RNA-seq studies in melanoma and RCC now reveal distinct subsets of exhausted T cells, characterized by high expression of PD−1, TOX, and CXCL13, suggesting specialized niches where these exhausted cells localize (26, 27). Therefore, the functional status of CD8+ T cells is pivotal in determining both patient prognosis and the efficacy of immunotherapies. Recent advances in single-cell RNA sequencing (scRNA-seq) have enabled detailed profiling of exhausted CD8+ T cells, and this technology has already been applied successfully in melanoma studies (28). Implementing scRNA-seq to characterize RCC-specific TME features may help elucidate the long-observed inverse association between CD8+ T cell infiltration and clinical outcomes in RCC (29).

2.2 Natural killer cells and immunosuppressive cells

NK cells are another major cytotoxic population capable of mediating anti-tumor immunity through perforin and interferon-γ (IFN-γ) release without prior sensitization (30). Remark et al. (31) demonstrated a positive correlation between NK cell infiltration and favorable prognosis in RCC. However, soluble cytokines, membrane-bound ligands, and TGF-β-enriched exosomes derived from tumor cells and immunosuppressive cells can inhibit NK cell degranulation and cytotoxicity (32–34). In addition to soluble TGF−β, RCC-derived exosomes carry TGF−β and immunomodulatory miRNAs (miR−23a, miR−146a), which are internalized by NK cells and lead to the downregulation of activating receptors such as NKG2D, NKp30, and NKp44 (35–38). This receptor loss reduces their ability to recognize and lyse tumor cells. Furthermore, CAFs secrete abundant prostaglandin E2 (PGE2), which acts on EP2/EP4 receptors expressed by NK cells (39, 40). Engagement of these receptors triggers the cAMP–PKA–CREB signaling cascade, suppressing the transcription of genes involved in cytotoxic granule formation and IFN−γ production (41–43). The net effect is impaired NK cell proliferation, decreased granule exocytosis, and weakened target cell killing capacity (44). These mechanisms, combined with other immunosuppressive metabolites (adenosine), synergistically dampen NK cell cytotoxicity within the RCC TME (45). Mechanistically, TGF−β binds TGFβRII on NK cells, activating SMAD2/3, which downregulates NKG2D and perforin expression; tumor-derived adenosine acts via A2A receptors to activate PKA signaling, suppressing NK metabolism and granule release (46–48). As a result, the functional capacity of tumor-infiltrating NK cells is often compromised. Therefore, strategies aimed at restoring NK cell activity are critical for enhancing the efficacy of ICIs in RCC (49).

Regulatory T cells (Tregs), a CD4+ T cell subset with immunosuppressive function, are essential for immune homeostasis but promote immune evasion in the RCC TME (50). Tumor and stromal cells secrete IL-10, IL-23, TGF-β, adenosine, and adhesion molecules to recruit Tregs, which suppress CD8+ T cells via TGF-β, IL-10, and IL-35 (51, 52). Although associated with poor prognosis, the precise role of Tregs in RCC remains unclear and requires further elucidation (53). Tumor-associated macrophages (TAMs), the dominant myeloid population in RCC, polarize into pro-inflammatory M1 and immunosuppressive M2 phenotypes (54). Elevated M2 or M2/M1 ratios correlate with poor outcomes (55). CSF1/CSF1R and IL−4/STAT6 signaling are major inducers of M2 polarization (56, 57). M2 TAMs secrete IL-10, CCL17/22, and VEGF, while activating PI3K/AKT and STAT3 pathways in tumor cells, which promotes proliferation and immune evasion (58–60). RCC-derived M-CSF promotes M2 polarization, comprising up to 20.9% of immune cells (61). M2-TAMs inhibit CD8+ T cell cytotoxicity, recruit suppressive cells, and remodel the ECM via MMPs, aiding invasion and metastasis (62). Chevrier et al. identified 17 TAM states, linking CD38+M5 TAMs to T cell exhaustion and Tregs, while high M11/M13 and low M5 TAM levels predicted shorter progression-free survival, suggesting therapeutic potential in TAM modulation. Myeloid-derived suppressor cells (MDSCs) inhibit CD8+ T cells through PD-L1 expression, ARG1-mediated amino acid depletion, and ADAM17-dependent T cell trafficking. MDSCs also promote immunosuppressive ECM remodeling via MMPs and iNOS (63, 64). ARG1 depletes arginine, limiting TCR ζ-chain expression; iNOS-derived NO leads to nitration of TCR complexes, impairing signal transduction, while NF-κB signaling within MDSCs maintains their suppressive function (65–67). Tie2-expressing monocytes (TEMs) facilitate angiogenesis and RCC progression (68). Neutrophil proteases also remodel the ECM via PAD4-mediated chromatin decondensation, promote invasion, induce T cell exclusion/exhaustion, and contribute to TKI resistance and poor prognosis in RCC (69).

2.3 Carcinoma-associated fibroblasts

CAFs, the most abundant stromal cell type in RCC, are central to tumor growth, metastasis, drug resistance, and immune evasion (70, 71). Under hypoxia and oxidative stress, tumor cells secrete TGF-β, IL-6, and platelet-derived growth factor (PDGF), activating CAF precursors, which upregulate fibroblast activation protein (FAP) (72). Activated CAFs stimulate pro-inflammatory signaling pathways such as STAT3 and NF-κB, and secrete hepatocyte growth factor (HGF), epidermal growth factor (EGF), and IL-6 to recruit Treg and activate immunosuppressive cells (73–75). Through secretion of TGF−β and ARG2, CAFs induce M2 polarization of TAMs and expansion of Tregs, while CXCL12 produced by CAFs engages CXCR4 on T cells, forming a “chemokine barrier” that excludes CD8+ T cells from tumor nests (76, 77). CAFs can also directly inhibit cytotoxic immune cells via TGF-β and ARG2 secretion (78). As “architects” of the TME, CAFs produce ECM components and facilitate tumor progression and metastasis (79, 80). The immunosuppressive nature of CAFs underlies the poor responsiveness of fibrotic tumors to therapy, yet their ubiquity offers multiple therapeutic targets (81, 82). Although anti-CAF therapies have shown promise in breast and pancreatic cancers, CAF heterogeneity across tumor types necessitates further investigation into RCC-specific CAF-targeting strategies (83).

2.4 Vascular endothelial cells

RCC is among the most vascularized tumors, a feature strongly associated with early biallelic inactivation of the tumor suppressor gene von Hippel–Lindau (VHL) (84). VHL negatively regulates hypoxia-inducible factor (HIF), and its loss leads to HIF accumulation and subsequent overproduction of vascular endothelial growth factor (VEGF), promoting tumor angiogenesis (85). VEGF binds VEGFR2 on endothelial cells, activating PI3K–AKT and MAPK/ERK pathways to promote angiogenesis. The resulting abnormal vessels express FasL and downregulate adhesion molecules (ICAM-1, VCAM-1), creating a physical and biochemical barrier to immune (86–88). Abnormal vasculature impairs perfusion, leading to hypoxia, acidosis, and reduced drug penetration. These conditions further induce immunosuppressive factors such as TGF-β, VEGF, and adenosine, and downregulate endothelial adhesion molecules, impeding immune cell adhesion, trafficking, and infiltration (89). While microvascular density serves as a prognostic indicator in cancers such as oral cancer, its prognostic value in RCC remains controversial due to variability in vascular morphology and differentiation (90, 91). Moreover, endothelial cells in RCC express high levels of indoleamine 2,3-dioxygenase (IDO) under IFN-γ stimulation, triggering tryptophan catabolism via the kynurenine pathway. Kynurenine activates aryl hydrocarbon receptor (AHR) in T cells, inducing FOXP3 expression and generating Tregs, further promoting immunosuppression (92).

2.5 Extracellular matrix and soluble factors

RCC progression involves extensive ECM deposition, providing structural support, biomechanical signaling, and regulation of cell behavior (93). The ECM, primarily secreted by CAFs, consists of collagens, laminins, glycoproteins, fibronectin, proteoglycans, and polysaccharides (94). Matrix remodeling is mediated by enzymes such as MMP2/9 and lysyl oxidase (LOX), which are activated by TGF−β and hypoxia (HIF−1α). These pathways stiffen the ECM and impair immune cell infiltration (95–97). TAMs, MDSCs, and CAFs secrete transglutaminases and lysyl oxidase, remodeling the ECM to induce collagen rearrangement, matrix stiffening, and reduced permeability, forming a barrier against cytotoxic immune infiltration (98). ECM remodeling also causes mechanical stress, impairing vascular function and promoting immune suppression (99). The remodeled ECM harbors abundant soluble mediators that facilitate bidirectional communication between tumor epithelial and stromal compartments, thereby promoting RCC invasion and metastasis (100, 101). Hypoxia and necrosis in rapidly growing tumors trigger the release of CSF-1, G-CSF, TGF-β, and chemokines (CCL2/3/4/7), recruiting myeloid cells (102–105). These cells, in turn, secrete VEGF, EGF, HGF, PDGF, CXCL12, and IL-8 to sustain tumor growth, angiogenesis, and immune infiltration (106, 107). In addition to amino acid depletion via iNOS and arginase-1, metabolic reprogramming driven by HIF signaling profoundly affects the immunosuppressive milieu (108, 109). RCC cells preferentially undergo aerobic glycolysis, resulting in excess lactate production and extracellular acidification (110). Elevated lactate concentrations reduce the glycolytic capacity of CD8+ T cells, suppress mTOR signaling, and promote a state of metabolic exhaustion (111). Lactate also enhances histone lactylation, which epigenetically upregulates PD−1 expression, thereby intensifying T cell dysfunction in synergy with PD−1/PD−L1 signaling (112, 113). Moreover, lactate accumulation favors the expansion of Tregs and M2-polarized macrophages, creating a positive feedback loop that reinforces immune evasion (114, 115). These mechanisms intersect with IDO- and arginase-mediated nutrient depletion, collectively dampening T cell activation and effector function within the RCC TME. Depletion of specific soluble factors also plays a critical role in immune evasion. Tumor cells consume large quantities of glucose and glutamine, the latter being essential for T-bet expression and CD4+ T cell differentiation (116). Enzymes such as iNOS and ARG1 from myeloid cells and CAFs and IDO from endothelial cells deplete essential amino acids and generate toxic metabolites, directly impairing T cell function (117) ( Table 1 ).

Table 1 Immunosuppressive components of the RCC tumor microenvironment and their roles in immune evasion.

ComponentFeaturesImmune MechanismsClinical ImpactTherapeutic Targets
Cytotoxic CD8+ T cellsHigh PD-1, CTLA-4, Tim-3 expression; low Ki-67; exhausted phenotypeImpaired antigen recognition, proliferation, and IL-2 secretion due to chronic immunosuppressive signalsMeta-analysis shows infiltration correlates with poor prognosis; functional status determines immunotherapy responsePD-1/CTLA-4 blockade, scRNA-seq-guided reinvigoration strategies
NK cellsMediate cytotoxicity via perforin/IFN-γ; inhibited by TGF-β, exosomes, and soluble ligandsDegranulation and cytotoxicity suppressed by TME-derived factorsInfiltration associated with favorable prognosis, but function often compromisedCytokine priming (IL-15), TGF-β inhibition, exosome blockade
TregsCD4+ subset recruited via IL-10, TGF-β, adenosine; suppress via IL-10/IL-35/TGF-βDirect inhibition of CD8+ T cells; promotion of T cell exhaustionHigh infiltration linked to poor prognosis, but role in RCC remains controversialDepletion (anti-CD25), TGF-β/IL-10 pathway inhibition
M2-TAMsDominant myeloid population (up to 20.9% of immune cells); polarized by M-CSFECM remodeling (MMPs), CD8+ T cell inhibition, recruitment of suppressive cells (Tregs, MDSCs)High M2/M1 ratio correlates with poor outcomes; CD38+M5 subset linked to T cell exhaustionCSF-1R inhibition, repolarization to M1 (TLR agonists)
MDSCsExpress PD-L1, ARG1, iNOS; secrete MMPsAmino acid depletion (ARG1), T cell trafficking inhibition (ADAM17), ECM remodelingPromote TKI resistance; correlate with advanced diseaseEntinostat (ARG1/iNOS suppression), CXCR4 antagonists (AMD3100)
CAFsActivated by TGF-β/IL-6/PDGF; secrete HGF, EGF, IL-6, ECM componentsDirect T cell suppression (TGF-β, ARG2); ECM stiffening; recruitment of immunosuppressive cellsFibrosis associated with therapy resistance; FAP expression predicts invasivenessFAP-targeted therapies (CAR-T, vaccines), STAT3/NF-κB inhibition
Abnormal VasculatureDriven by VHL-HIF-VEGF axis; dysfunctional perfusionHypoxia-induced TGF-β/VEGF/adenosine; impaired immune cell adhesion/traffickingMicrovascular density prognostic value debated; IDO+ endothelial cells promote immune evasionVEGF inhibitors (axitinib), IDO blockade (epacadostat)
ECM RemodelingCollagens, fibronectin, proteoglycans stiffened by LOX/transglutaminases (from CAFs/TAMs/MDSCs)Physical barrier to immune infiltration; mechanical stress impairs vascular functionCorrelates with advanced stage and metastasisLOX/MMP inhibitors, mechanotherapy (YAP/TAK1 targeting)

3 Biomarkers for immunotherapy

3.1 PD-L1 expression and tumor-infiltrating lymphocytes

Numerous clinical trials in RCC have reported that only a small subset of patients can achieve complete response and tolerate long-term immunotherapy, while the majority experience disease progression (118, 119). Therefore, the identification of reliable biomarkers capable of predicting immunotherapeutic response is critical for selecting patients most likely to benefit from such treatments (120, 121). Tumor PD-L1 expression is the most widely used biomarker for predicting responses to PD-1/PD-L1 blockade therapy and one of the earliest predictive indicators studied in RCC (122). Although high PD-L1 expression in RCC tissues has been associated with poor prognosis, PD-L1 alone is insufficient to predict therapeutic efficacy (123). Stenzel et al. (124) demonstrated that tumor tissues from patients with ccRCC who responded favorably to ICIs exhibited significantly higher CD8+ T cell infiltration and PD-L1 positivity compared to non-responders. ICIs can reinvigorate pre-existing Th1 cells within the TME, enabling cytotoxic responses against tumor cells (125, 126). This seemingly paradoxical relationship between PD-L1 expression, poor prognosis, and ICI responsiveness may reflect both the spatial heterogeneity of PD-L1 expression in tumor cells and its dynamic regulation: inducible PD-L1 upregulation by IFN−γ released during an active anti-tumor immune response versus constitutive PD-L1 expression driven by HIF−1α in hypoxic regions (127). These mechanisms highlight that PD-L1 expression must be interpreted in the context of the tumor microenvironment and cellular localization (128, 129). Therefore, patients with this immune phenotype are more likely to benefit from ICI therapy.

3.2 Gene mutations

TMB and microsatellite instability (MSI) are well-established predictive biomarkers for ICI efficacy across several malignancies (130, 131). It is generally accepted that tumor-specific neoantigens generated by somatic mutations facilitate immune infiltration, a prerequisite for ICI responsiveness (132, 133). Despite the high immune infiltration in RCC, TMB levels are significantly lower compared to other immunogenic tumors such as lung adenocarcinoma and melanoma (134). A pan-cancer analysis of 19 malignancies by Turajlic et al. (135) using The Cancer Genome Atlas (TCGA) data revealed that RCC harbors the highest frequency and count of insertion or deletion (indel) mutations—over twice the average observed in other cancers. Further RNA sequencing of 329 RCC samples confirmed that indel mutations are associated with heightened immunogenicity, suggesting that indels may serve as superior predictive biomarkers compared to TMB in RCC. Over 90% of sporadic ccRCC cases involve chromosomal translocations at 3p, leading to frequent mutations in VHL, PBRM1, BAP1, and SETD2. Consequently, RCC is considered a disease defined by genomic rearrangements (136). Messai et al. (137) reported a positive correlation between VHL mutations and PD-L1 expression in ccRCC, which may influence patient responses to immunotherapy. In a prospective study, Miao et al. (138) performed whole-exome sequencing on tumor tissues from 35 untreated mRCC patients and found that loss-of-function mutations in PBRM1 were associated with enhanced responsiveness to ICIs, a finding subsequently validated in independent cohorts. A retrospective analysis of the CheckMate 025 trial further demonstrated that PBRM1-mutant RCC patients experienced significantly prolonged progression-free survival (PFS) and overall survival (OS) following anti-PD-1 therapy (139). Mechanistically, loss of PBRM1 disrupts the SWI/SNF chromatin remodeling complex, leading to changes in nucleosome positioning and transcriptional accessibility of interferon-stimulated genes (140). This epigenetic reprogramming can activate the STING–type I interferon pathway, increasing tumor immunogenicity and chemokine production (CXCL10, CCL5), thereby enhancing dendritic cell recruitment and T cell priming (141, 142). Additionally, PBRM1 deficiency has been associated with increased expression of MHC II molecules and components of the antigen-processing machinery, potentially improving tumor antigen presentation and amplifying CD8+ T cell responses (143, 144).

3.3 Emerging biomarkers

Clark et al. (136) utilized xCell to analyze the immune and stromal components of 103 ccRCC samples, integrating transcriptomic and proteomic data to classify ccRCC into four distinct subtypes: CD8+ inflamed tumors, CD8− inflamed tumors, VEGF-high immune desert tumors, and metabolically active immune desert tumors. CD8+ inflamed tumors are characterized by extensive CD8+ T cell infiltration and elevated expression of inhibitory receptors such as PD-1, PD-L1, and CTLA-4, conferring poor prognosis but high potential for immunotherapy response. CD8− inflamed tumors exhibit infiltration by CAFs and innate immune cells such as TAMs. VEGF-high immune desert tumors display pronounced vascularization due to elevated VEGF expression. Metabolically active immune desert tumors, with the lowest immune and stromal scores, exhibit upregulated expression of metabolic enzymes such as pyruvate kinase M (PKM) and peroxiredoxin-4 (PRDX4), along with activation of MYC and mTOR signaling pathways, indicative of tumor metabolic reprogramming. The Lung Immune Prognostic Index (LIPI) has recently emerged as a novel biomarker for immunotherapy, offering a valuable tool for risk stratification and personalized treatment decision-making across various malignancies. Initially applied in non-small cell lung cancer, melanoma, small cell lung cancer, head and neck squamous cell carcinoma, and bladder cancer, LIPI has also shown prognostic relevance in advanced RCC (145). Low-density lipoprotein receptor-related protein 6 (LRP6), a co-receptor in the Wnt/β-catenin signaling pathway involved in cell proliferation, inflammation, and transformation, has been correlated with drug sensitivity in clear cell RCC, suggesting its potential as a therapeutic target (146). Additionally, modulation of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) signaling has been proposed as a novel approach in cancer immunotherapy. CEACAM1 expression is associated with disease progression, prognosis, and immune cell infiltration in clear cell RCC, highlighting its promise as both a predictive biomarker and a therapeutic target (147).

4 Immunotherapy

4.1 Immune checkpoint inhibitors

Preclinical studies have delineated the biological roles of PD-1, PD-L1, and CTLA-4, enabling clinical trials of ICIs for advanced RCC (148–150). CTLA-4, expressed on activated T cells, binds B7 molecules on antigen-presenting cells (APCs), inhibiting T cell activation (151). Ipilimumab, an anti-CTLA-4 antibody, restores T cell function by blocking CD80/CD86 interactions but has limited clinical utility due to a narrow therapeutic window (152). PD-1, another inhibitory checkpoint, binds PD-L1/PD-L2 on tumor cells, suppressing T cell activity. Nivolumab, a PD-1 inhibitor, showed superior OS and objective response rate (ORR) versus everolimus in the CheckMate-025 trial, leading to FDA approval for mRCC (150). Beyond PD-1/CTLA-4, other checkpoints like TIM-3, LAG-3, KIRs, and TIGIT modulate T cell function via distinct mechanisms, potentially compromising immunotherapy efficacy (153). Targeting these pathways is under clinical investigation in RCC (154). To enhance immunotherapy efficacy, clinical trials have investigated combining anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies or TKIs as first-line RCC treatments, demonstrating superior outcomes to TKI monotherapy (44). While both PD-1 and CTLA-4 inhibit T cell activation, CTLA-4 acts early in T cell priming, whereas PD-1 suppresses CD8+ T cell effector function in the TME (155). Dual blockade synergistically boosts CD8+ T cell activation and accumulation (156). The CheckMate-214 trial showed ipilimumab-nivolumab improved PFS, ORR, and OS in intermediate-/high-risk RCC versus sunitinib, leading to its approval for these patients (157).

In breast cancer models, ICIs activate CD8+ T cells, inducing tumor vessel normalization, which alleviates TME immunosuppression, enhancing T cell infiltration and cytotoxicity—a positive feedback loop underpinning ICI combinations (158). The KEYNOTE-426 trial reported pembrolizumab-axitinib outperformed sunitinib across risk groups and PD-L1 levels (159), while JAVELIN Renal-101 showed avelumab-axitinib improved PFS by 6.6 months versus axitinib alone (160). These results led to FDA approval of both ICI-TKI regimens. The CLEAR study revealed lenvatinib-pembrolizumab provided durable survival benefits over sunitinib (160). Despite their frontline status, combination therapies are not universally effective and may cause severe toxicity. In KEYNOTE-426, pembrolizumab-axitinib frequently induced diarrhea, hypertension, and hepatic toxicity, with 30.5% discontinuing at least one drug due to adverse events (159). Biomarker-driven patient stratification is crucial to mitigate toxicity and costs, alongside deeper investigation of drug interactions to guide monotherapy or sequential approaches when appropriate.

4.2 Targeting immunosuppressive cells

Current therapeutic strategies targeting immunosuppressive cells in the RCC TME can be broadly categorized into three types (161). The first strategy involves depleting immunosuppressive cells to restore CD8+ T cell infiltration and enhance anti-tumor immunity. Fibroblast activation protein (FAP), a surface marker broadly expressed by CAFs in epithelial tumors, is a strong predictor of tumor invasiveness. Agents that inhibit FAP activity, anti-FAP antibodies, FAP-targeted vaccines, and CAR-T cell therapy have shown efficacy in depleting CAFs in preclinical models of malignancies such as mesothelioma (162). The second strategy aims to normalize immunosuppressive cells by inducing CAF quiescence, promoting MDSC maturation, or repolarizing M2-type TAMs. In murine RCC models, entinostat suppressed the immunosuppressive activity of MDSCs by inhibiting ARG1 and iNOS, thereby enhancing CD8+ T cell infiltration (16). The combination of entinostat with atezolizumab and bevacizumab is currently being tested in clinical trials for advanced RCC (NCT03024437). The third strategy focuses on modulating downstream pathways of immunosuppressive cells. The CXCR4–CXCL12 axis plays a critical role in the recruitment of MDSCs and Tregs to the RCC TME. The CXCR4 antagonist AMD3100 has been shown to impair the immunosuppressive function of these cells and improve anti-tumor immune responses (163). Given the frequent occurrence of mutations in metabolism-related genes, RCC is also considered a metabolic disease. Metabolic reprogramming in RCC involves aerobic glycolysis, fatty acid metabolism, and the utilization of tryptophan, glutamine, and arginine, enabling tumor cells to adapt to hypoxia and nutrient depletion while evading immune surveillance (164). IDO contributes to local tryptophan depletion in the TME via the kynurenine pathway, leading to T cell exhaustion and apoptosis. Thus, IDO inhibition can relieve local immune suppression and enhance T cell activity (165). A phase I/II clinical trial is currently evaluating the combination of the IDO inhibitor epacadostat with the anti-PD-1 antibody pembrolizumab in various solid tumors, including RCC, with promising results previously reported in melanoma (166–168). Inhibitors of HIF-α and glutaminase have also entered clinical trials for RCC (169, 170) ( Figure 1 ).

Diagram illustrating the tumor microenvironment in renal cell carcinoma, highlighting interactions among immune cells, cytokines, and signaling pathways. Includes regions on cytotoxic and immunosuppressive cells, signaling pathways involving TGF-β and interleukins, effects on tumor growth, and immunotherapy strategies such as ICIs and targeted therapies.

Figure 1 Tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma.

4.3 Clinical strategies to overcome resistance and manage toxicity

The clinical application of immunotherapy in RCC is constrained by tumor heterogeneity, acquired resistance, and treatment-related toxicity, and overcoming these challenges requires an integrated approach (171). Recent progress emphasizes adaptive and biomarker-driven trial designs which stratify patients according to PD−L1 expression, PBRM1 mutation status, or immune subtype to achieve precision therapy (172–174). Another key strategy is sequencing therapy rather than administering agents concurrently; for example, initiating treatment with TKIs to normalize aberrant vasculature and subsequently introducing ICIs can enhance immune cell infiltration while reducing overlapping toxicities (175). Efforts to counteract resistance also include the incorporation of novel agents such as TAM-reprogramming compounds, selective HIF−2α inhibitors, and metabolic modulators into combination regimens to disrupt pro-tumorigenic pathways (176, 177). Equally important is the proactive management of immune-related adverse events, which relies on early recognition, multidisciplinary collaboration, and the use of standardized treatment algorithms with corticosteroids or selective immunosuppressants to preserve antitumor activity (178, 179). Together, these strategies are shaping current and future clinical trials and provide clinicians with practical guidance to optimize therapeutic outcomes while minimizing toxicity in patients with RCC.

5 Conclusion

The immunosuppressive TME of RCC remains a major barrier to durable therapeutic responses, despite significant progress in immunotherapy. The interplay between cytotoxic immune cells and immunosuppressive components creates a permissive niche for tumor progression. While ICIs and combination therapies have revolutionized treatment, their efficacy is limited by intrinsic and acquired resistance, as well as toxicity. Biomarkers such as PD-L1, TMB, and PBRM1 mutations offer predictive insights but lack universal applicability, highlighting the need for multi-parametric profiling. Emerging strategies, including TAM repolarization, CAF depletion, metabolic modulation, and targeting novel immune checkpoints, hold promise but require further validation in clinical trials.

Looking ahead, advanced technologies will be pivotal in overcoming these limitations. Single-cell multi-omics and spatial transcriptomics enable high-resolution mapping of cellular states, lineage trajectories, and intercellular communication within the RCC TME, providing insights that bulk analyses cannot capture. These approaches will help to identify novel cellular subsets, spatially restricted immunosuppressive niches, and potential therapeutic targets. Additionally, artificial intelligence and machine learning are increasingly being applied to integrate multi-dimensional datasets, including genomics, transcriptomics, imaging, and clinical data, to develop predictive models for patient stratification and to discover novel biomarkers. Together, these emerging technologies hold great promise for bridging existing knowledge gaps, enabling real-time monitoring of TME evolution, and guiding the development of precision immunotherapies tailored to individual RCC patients. Moving forward, integrating these innovations with multi-omics profiling and optimizing treatment sequencing will be critical to overcoming resistance and improving outcomes. Ultimately, a precision medicine approach, guided by TME dynamics and predictive biomarkers, will be essential to unlocking the full potential of immunotherapy in RCC.

Author contributions

HW: Writing – original draft. SZ: Writing – original draft. XZ: Writing – original draft. LW: Writing – review & editing, Writing – original draft. DC: Writing – original draft, Writing – review & editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. 1 BrayFLaversanneMSungHFerlayJSiegelRLSoerjomataramIet al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74 (3):12–49. doi: 10.3322/caac.21834, PMID: 38572751
  2. 2 BahadoramSDavoodiMHassanzadehSBahadoramMBarahmanMMafakherL. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. (2022) 39:2022–vol3., PMID: 35819037
  3. 3 BarataPCRiniBI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. (2017) 67:507–24. doi: 10.3322/caac.21411, PMID: 28961310
  4. 4 LinGYangYFengQZhanFSunCNiuYet al.. Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma. Immunogenetics. (2022) 74:285–301. doi: 10.1007/s00251-021-01246-1, PMID: 35119508
  5. 5 HeoJJoYYoonM. Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma. Clin Transl Oncol. (2025) 40126769. doi: 10.1007/s12094-025-03898-x, PMID: 40126769
  6. 6 TorrisiMGianniniLTummineriRDeantoniCLFodorA. Excellent outcomes with stereotactic body radiotherapy in an elderly patient with locally progressive immunotherapy-resistant renal cell carcinoma. Cureus. (2025) 17:e85399. doi: 10.7759/cureus.85399, PMID: 40621365 PMC12228427
  7. 7 XuWWuYLiuWAnwaierATianXSuJet al.. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. Int J Biol Sci. (2022) 18:4884–900. doi: 10.7150/ijbs.74647, PMID: 35982911 PMC9379407
  8. 8 XuWLuJLiuWRAnwaierAWuYTianXet al.. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. J Immunother Cancer. (2023) 11:e006667. doi: 10.1136/jitc-2023-006667, PMID: 38040418 PMC10693897
  9. 9 DecruyenaereAChristineGSylvieRAnnouschkaLSerontEEveraertEet al.. Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Acta Oncol. (2025) 64:979–88. doi: 10.2340/1651-226X.2025.43876, PMID: 40734572 PMC12320143
  10. 10 AuLHatipogluERobert de MassyMLitchfieldKBeattieGRowanAet al.. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. (2021) 39:1497–1518.e1411. doi: 10.1016/j.ccell.2021.10.001, PMID: 34715028 PMC8599450
  11. 11 YanagisawaTSchmidingerMKawadaTBekkuKKimuraTShariatSF. Radical nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol Focus. (2023) 9:275–7. doi: 10.1016/j.euf.2023.01.022, PMID: 36775716
  12. 12 SalibyRMLabakiCJammihalTRXieWSunMShahVet al.. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. (2024) 42:732–5. doi: 10.1016/j.ccell.2024.03.002, PMID: 38579722 PMC11130783
  13. 13 ZhangMXJingLYTanHTDaiZRLongDZLiuHCet al.. MIAT promotes tumor-infiltrating CD8(+) T-cell exhaustion and Malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway. J Immunother Cancer. (2025) 13:e011162. doi: 10.1136/jitc-2024-011162, PMID: 40744660 PMC12314945
  14. 14 GranierCDarianeCCombePVerkarreVUrienSBadoualCet al.. Tim-3 expression on tumor-infiltrating PD-1(+)CD8(+) T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. (2017) 77:1075–82. doi: 10.1158/0008-5472.CAN-16-0274, PMID: 27872087
  15. 15 FridmanWHPagèsFSautès-FridmanCGalonJ. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. (2012) 12:298–306. doi: 10.1038/nrc3245, PMID: 22419253
  16. 16 DeleuzeASaoutJDugayFPeyronnetBMathieuRVerhoestGet al.. Immunotherapy in renal cell carcinoma: the future is now. Int J Mol Sci. (2020) 21:2532. doi: 10.3390/ijms21072532, PMID: 32260578 PMC7177761
  17. 17 PontrelliPGiganteMSpadaccinoFNettiGSSaldarelliMBalducciLet al.. CD40 cross-linking induces migration of renal tumor cell through nuclear factor of activated T cells (NFAT) activation. Int J Mol Sci. (2021) 22:8871. doi: 10.3390/ijms22168871, PMID: 34445576 PMC8396205
  18. 18 ZhangCGouXLaiGLiKZhuXLiuNet al.. Single-nucleus sequencing unveils heterogeneity in renal cell carcinomas microenvironment: Insights into pathogenic origins and treatment-responsive cellular subgroups. Cancer Lett. (2024) 604:217259. doi: 10.1016/j.canlet.2024.217259, PMID: 39278398
  19. 19 ZapałaŁKuncMSharmaSPęksaRPopędaMBiernatWet al.. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus. J Cancer Res Clin Oncol. (2023) 149:4131–9. doi: 10.1007/s00432-022-04329-y, PMID: 36042047 PMC10314835
  20. 20 ZhuZJinYZhouJChenFChenMGaoZet al.. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. (2024) 23:146. doi: 10.1186/s12943-024-02059-y, PMID: 39014460 PMC11251344
  21. 21 WuDZhouYShiXYiXShengZFanLet al.. SLC11A1 promotes kidney renal clear cell carcinoma (KIRC) progression by remodeling the tumor microenvironment. Toxicol Appl Pharmacol. (2024) 487:116975. doi: 10.1016/j.taap.2024.116975, PMID: 38762191
  22. 22 CimadamoreABoixareuCSharpABeltranHde BonoJS. Novel therapeutic strategies for metastatic prostate cancer care. Eur Urol. (2025) 19:S0302-2838(25)00357-4. doi: 10.1016/j.eururo.2025.06.013, PMID: 40685286 PMC12954635
  23. 23 KawaseKKawashimaSNishiTInozumeTMorinagaTKawazuMet al.. PI3K/Akt signaling pathway regulates CD155 expression involved in resistance to cancer immunotherapy. Cancer Immunol Res. (2025) 40742385. doi: 10.1158/2326-6066.CIR-24-0853, PMID: 40742385
  24. 24 YochumZABraunDA. Immunotherapy for renal cell carcinoma-what more is to come? Target Oncol. (2025) 20:467–83. doi: 10.1007/s11523-025-01143-7, PMID: 40208564
  25. 25 AndrzejczakATupikowskiKTomkiewiczAMałkiewiczBPtaszkowskiKDominAet al.. The variations’ in genes encoding TIM-3 and its ligand, galectin-9, influence on ccRCC risk and prognosis. Int J Mol Sci. (2023) 24:2042. doi: 10.3390/ijms24032042, PMID: 36768365 PMC9917084
  26. 26 ZhangJPengQFanJLiuFChenHBiXet al.. Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC. J Transl Med. (2024) 22:1157. doi: 10.1186/s12967-024-06018-5, PMID: 39736762 PMC11687132
  27. 27 NingKPengYJiangYLiZLuoXLinLet al.. Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8(+) T-cells highly infiltrated in males. Biol Sex Differ. (2023) 14:58. doi: 10.1186/s13293-023-00540-9, PMID: 37715192 PMC10503187
  28. 28 ChenWJCaoHCaoJWZuoLQuFJXuDet al.. Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study. Cell Death Dis. (2022) 13:50. doi: 10.1038/s41419-022-04501-9, PMID: 35017463 PMC8752784
  29. 29 LiuXJiangRXuYXuXFangLGaoGet al.. Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma. Int Immunopharmacol. (2025) 156:114725. doi: 10.1016/j.intimp.2025.114725, PMID: 40294469
  30. 30 LiuSGalatVGalatYLeeYKAWainwrightDWuJ. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. (2021) 14:7. doi: 10.1186/s13045-020-01014-w, PMID: 33407739 PMC7788999
  31. 31 RemarkRAlifanoMCremerILupoADieu-NosjeanMCRiquetMet al.. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. (2013) 19:4079–91. doi: 10.1158/1078-0432.CCR-12-3847, PMID: 23785047
  32. 32 XiaYZhangQZhenQZhaoYLiuNLiTet al.. Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway. Oncotarget. (2017) 8:37783–95. doi: 10.18632/oncotarget.16354, PMID: 28384121 PMC5514949
  33. 33 JiaHYangHXiongHLuoKQ. NK cell exhaustion in the tumor microenvironment. Front Immunol. (2023) 14:1303605. doi: 10.3389/fimmu.2023.1303605, PMID: 38022646 PMC10653587
  34. 34 HosseiniRSarvnazHArabpourMRamsheSMAsef-KabiriLYousefiHet al.. Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. Mol Cancer. (2022) 21:15. doi: 10.1186/s12943-021-01492-7, PMID: 35031075 PMC8759167
  35. 35 ShenTMiaoSZhouYYiXXueSDuBet al.. Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3. Cell Commun Signal. (2022) 20:152. doi: 10.1186/s12964-022-00957-6, PMID: 36153596 PMC9509597
  36. 36 BerchemGNomanMZBosselerMPaggettiJBaconnaisSLe CamEet al.. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncoimmunology. (2016) 5:e1062968. doi: 10.1080/2162402X.2015.1062968, PMID: 27141372 PMC4839360
  37. 37 ShafferTMAalipourASchürchCMGambhirSS. PET imaging of the natural killer cell activation receptor NKp30. J Nucl Med. (2020) 61:1348–54. doi: 10.2967/jnumed.119.233163, PMID: 32532927 PMC7456168
  38. 38 TrottaAMSantagataSZanottaSD’AlterioCNapolitanoMReaGet al.. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity. J Exp Clin Cancer Res. (2018) 37:297. doi: 10.1186/s13046-018-0952-7, PMID: 30514329 PMC6278085
  39. 39 ZhangYThayele PurayilHBlackJBFettoFLynchLDMasannatJNet al.. Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis. Cancer Lett. (2017) 391:50–8. doi: 10.1016/j.canlet.2017.01.007, PMID: 28104442 PMC5340307
  40. 40 ParkGSongNYKimDHLeeSJChunKS. Thymoquinone suppresses migration of human renal carcinoma caki-1 cells through inhibition of the PGE(2)-mediated activation of the EP2 receptor pathway. Biomol Ther (Seoul). (2021) 29:64–72. doi: 10.4062/biomolther.2020.048, PMID: 32843585 PMC7771838
  41. 41 YanCYangZChenPYehYSunCXieTet al.. GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression. J Exp Clin Cancer Res. (2024) 43:105. doi: 10.1186/s13046-024-03025-8, PMID: 38576043 PMC10993467
  42. 42 LiuLWangYFanYLiCLChangZL. IFN-gamma activates cAMP/PKA/CREB signaling pathway in murine peritoneal macrophages. J Interferon Cytokine Res. (2004) 24:334–42. doi: 10.1089/107999004323142196, PMID: 15212707
  43. 43 HuSChenBZhouJLiuFMaoTPathakJLet al.. Dental pulp stem cell-derived exosomes revitalize salivary gland epithelial cell function in NOD mice via the GPER-mediated cAMP/PKA/CREB signaling pathway. J Transl Med. (2023) 21:361. doi: 10.1186/s12967-023-04198-0, PMID: 37268950 PMC10239098
  44. 44 ZhaoWHuangYLiuZCaoBBPengYPQiuYH. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PloS One. (2013) 8:e65860. doi: 10.1371/journal.pone.0065860, PMID: 23799052 PMC3683046
  45. 45 Monjaras-AvilaCULorenzo-LealACLuque-BadilloACD’CostaNChavez-MuñozCBachH. The tumor immune microenvironment in clear cell renal cell carcinoma. Int J Mol Sci. (2023) 24:7946. doi: 10.3390/ijms24097946, PMID: 37175653 PMC10178526
  46. 46 KajdaniukDHudyDStrzelczykJKMłynarekKSłomianSPotykaAet al.. Transforming growth factors β and their signaling pathway in renal cell carcinoma and peritumoral space-transcriptome analysis. Clin Transl Oncol. (2024) 26:1229–39. doi: 10.1007/s12094-023-03350-y, PMID: 38085441 PMC11026247
  47. 47 WangYDingWHaoWGongLPengYZhangJet al.. CXCL3/TGF-β-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance. iScience. (2024) 27:110224. doi: 10.1016/j.isci.2024.110224, PMID: 39040058 PMC11261419
  48. 48 XuSZhangZHFuLSongJXieDDYuDXet al.. Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/3-, STAT3- and β-catenin-mediated epithelial-mesenchymal transition. Cancer Sci. (2020) 111:59–71. doi: 10.1111/cas.14237, PMID: 31729097 PMC6942435
  49. 49 LiXZhangYYeYXiaoWLiuLZhangX. NK cells in renal cell carcinoma and its implications for CAR-NK therapy. Front Cell Dev Biol. (2025) 13:1532491. doi: 10.3389/fcell.2025.1532491, PMID: 40052147 PMC11882582
  50. 50 LiZMaJXuMDuanYHuangCDaiQet al.. Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies. Int Immunopharmacol. (2025) 163:115322. doi: 10.1016/j.intimp.2025.115322, PMID: 40763476
  51. 51 SantagataSReaGBelloAMCapiluongoANapolitanoMDesicatoSet al.. Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients. Br J Cancer. (2024) 130:2016–26. doi: 10.1038/s41416-024-02702-x, PMID: 38704478 PMC11183124
  52. 52 Sasidharan NairVElkordE. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol. (2018) 96:21–33. doi: 10.1111/imcb.1003, PMID: 29359507
  53. 53 SongXZhuYGengWJiaoJLiuHChenRet al.. Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma. J Immunother Cancer. (2025) 13:e010183. doi: 10.1136/jitc-2024-010183, PMID: 39755578 PMC11748785
  54. 54 ZhangXSunYMaYGaoCZhangYYangXet al.. Tumor-associated M2 macrophages in the immune microenvironment influence the progression of renal clear cell carcinoma by regulating M2 macrophage-associated genes. Front Oncol. (2023) 13:1157861. doi: 10.3389/fonc.2023.1157861, PMID: 37361571 PMC10285481
  55. 55 LiuHLvZZhangGYanZBaiSDongDet al.. Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma. J Exp Clin Cancer Res. (2024) 43:242. doi: 10.1186/s13046-024-03164-y, PMID: 39169402 PMC11340075
  56. 56 ZhouYZengJTuYLiLDuSZhuLet al.. CSF1/CSF1R-mediated crosstalk between choroidal vascular endothelial cells and macrophages promotes choroidal neovascularization. Invest Ophthalmol Vis Sci. (2021) 62:37. doi: 10.1167/iovs.62.3.37, PMID: 33764399 PMC7995352
  57. 57 LiangWWuHLongQLinHLvXMaWet al.. LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization. Life Sci. (2025) 370:123564. doi: 10.1016/j.lfs.2025.123564, PMID: 40097066
  58. 58 ZhaoSMiYGuanBZhengBWeiPGuYet al.. Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J Hematol Oncol. (2020) 13:156. doi: 10.1186/s13045-020-00991-2, PMID: 33213490 PMC7678301
  59. 59 LiDZhangQLiLChenKYangJDixitDet al.. β2-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages. Cancer Res. (2022) 82:3321–34. doi: 10.1158/0008-5472.CAN-22-0507, PMID: 35841593
  60. 60 LvJLiuCChenFKFengZPJiaLLiuPJet al.. M2−like tumour−associated macrophage−secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway. Mol Med Rep. (2021) 24:604. doi: 10.3892/mmr.2021.12249, PMID: 34184083 PMC8258465
  61. 61 PanQWangLChaiSZhangHLiB. The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. (2020) 11:3207–15. doi: 10.7150/jca.37285, PMID: 32231726 PMC7097965
  62. 62 YangYLiSToKKWZhuSWangFFuL. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res. (2025) 44:145. doi: 10.1186/s13046-025-03377-9, PMID: 40380196 PMC12083052
  63. 63 GrothCHuXWeberRFlemingVAltevogtPUtikalJet al.. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. (2019) 120:16–25. doi: 10.1038/s41416-018-0333-1, PMID: 30413826 PMC6325125
  64. 64 RodriguezPCErnstoffMSHernandezCAtkinsMZabaletaJSierraRet al.. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. (2009) 69:1553–60. doi: 10.1158/0008-5472.CAN-08-1921, PMID: 19201693 PMC2900845
  65. 65 ZengQLYangBSunHQFengGHJinLZouZSet al.. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients. Mol Cells. (2014) 37:66–73. doi: 10.14348/molcells.2014.2282, PMID: 24552712 PMC3907002
  66. 66 HeSTianWZhaoJGongRWangTMaL. Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1/COX-2/iNOS signaling pathway. Transl Cancer Res. (2022) 11:206–16. doi: 10.21037/tcr-21-2534, PMID: 35261897 PMC8841661
  67. 67 SongWLiDTaoLLuoQChenL. Solute carrier transporters: the metabolic gatekeepers of immune cells. Acta Pharm Sin B. (2020) 10:61–78. doi: 10.1016/j.apsb.2019.12.006, PMID: 31993307 PMC6977534
  68. 68 ZhangXJiJZhangGFangCJiangFMaSet al.. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma. Onco Targets Ther. (2017) 10:5417–24. doi: 10.2147/OTT.S147041, PMID: 29180874 PMC5692197
  69. 69 CarnevaleRLeopizziMDominiciMd’AmatiGBartimocciaSNocellaCet al.. PAD4-induced NETosis via cathepsin G-mediated platelet-neutrophil interaction in chAdOx1 vaccine-induced thrombosis-brief report. Arterioscler Thromb Vasc Biol. (2023) 43:e396–403. doi: 10.1161/ATVBAHA.123.319522, PMID: 37586040
  70. 70 DingMZhaoXChenXDiaoWKanYCaoWet al.. Cancer-associated fibroblasts promote the stemness and progression of renal cell carcinoma via exosomal miR-181d-5p. Cell Death Discov. (2022) 8:439. doi: 10.1038/s41420-022-01219-7, PMID: 36319622 PMC9626570
  71. 71 KraxnerABraunFChengWYYangTOPipaliyaSCanameroMet al.. Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy. Front Immunol. (2024) 15:1352632. doi: 10.3389/fimmu.2024.1352632, PMID: 39035007 PMC11258004
  72. 72 YanJXiaoGYangCLiuQLvCYuXet al.. Cancer-associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB/PDGFR-β Mediated paracrine signaling network. Aging Dis. (2024) 15:369–89. doi: 10.14336/AD.2023.0420, PMID: 37307823 PMC10796099
  73. 73 MaJCaoDZhangYSunYWuYWangJ. Bruceine D inhibits CAF-promoted angiogenesis of breast cancer via suppressing IL-6-mediated activation of the STAT3/Notch1/VEGFR2 axis. Eur J Pharmacol. (2025) 1003:177994. doi: 10.1016/j.ejphar.2025.177994, PMID: 40714073
  74. 74 SongXLiTZhouWFengCZhouZChenYet al.. CAF-derived exosomal miR-196b-5p after androgen deprivation therapy promotes epithelial-mesenchymal transition in prostate cancer cells through HOXC8/NF-κB signaling pathway. Biol Direct. (2025) 20:80. doi: 10.1186/s13062-025-00667-2, PMID: 40615904 PMC12232169
  75. 75 LiYZhengHLuoYLinYAnMKongYet al.. An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. Cancer Commun (Lond). (2023) 43:1289–311. doi: 10.1002/cac2.12470, PMID: 37483113 PMC10693311
  76. 76 LuoFMeiYLiYYangJXiSCaoEet al.. CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma. Neuro Oncol. (2025) 26:noaf157. doi: 10.1093/neuonc/noaf157, PMID: 40569145 PMC12908487
  77. 77 AronovichAMoyalLGorovitzBAmitay-LaishINavehHPForerYet al.. Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12/CXCR4. J Invest Dermatol. (2021) 141:619–627.e612. doi: 10.1016/j.jid.2020.06.034, PMID: 32795528
  78. 78 PengDFuMWangMWeiYWeiX. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. (2022) 21:104. doi: 10.1186/s12943-022-01569-x, PMID: 35461253 PMC9033932
  79. 79 ArpinatiLCarradoriGScherz-ShouvalR. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer. (2024) 24:676–93. doi: 10.1038/s41568-024-00740-4, PMID: 39251836
  80. 80 ZhangRLiuF. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients. J Transl Med. (2022) 20:453. doi: 10.1186/s12967-022-03656-5, PMID: 36195908 PMC9533530
  81. 81 XuCZhangKYangFZhouXLiuSLiYet al.. CD248(+) cancer-associated fibroblasts: A novel prognostic and therapeutic target for renal cell carcinoma. Front Oncol. (2021) 11:773063. doi: 10.3389/fonc.2021.773063, PMID: 34970489 PMC8712640
  82. 82 MaoXXuJWangWLiangCHuaJLiuJet al.. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. (2021) 20:131. doi: 10.1186/s12943-021-01428-1, PMID: 34635121 PMC8504100
  83. 83 LavieDBen-ShmuelAErezNScherz-ShouvalR. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. (2022) 3:793–807. doi: 10.1038/s43018-022-00411-z, PMID: 35883004 PMC7613625
  84. 84 RoseTLKimWY. Renal cell carcinoma: A review. Jama. (2024) 332:1001–10. doi: 10.1001/jama.2024.12848, PMID: 39196544 PMC11790279
  85. 85 LiQZengKChenQHanCWangXLiBet al.. Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2α. Autophagy. (2025) 21:619–38. doi: 10.1080/15548627.2024.2421699, PMID: 39477683 PMC11849937
  86. 86 Tumkur SitaramRLandströmMRoosGLjungbergB. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. J Clin Pathol. (2021) 74:216–22. doi: 10.1136/jclinpath-2020-206693, PMID: 32467322
  87. 87 LeiYChenXMoJLLvLLKouZWSunFY. Vascular endothelial growth factor promotes transdifferentiation of astrocytes into neurons via activation of the MAPK/Erk-Pax6 signal pathway. Glia. (2023) 71:1648–66. doi: 10.1002/glia.24361, PMID: 36960578
  88. 88 ChenJGuZWuMYangYZhangJOuJet al.. C-reactive protein can upregulate VEGF expression to promote ADSC-induced angiogenesis by activating HIF-1α via CD64/PI3k/Akt and MAPK/ERK signaling pathways. Stem Cell Res Ther. (2016) 7:114. doi: 10.1186/s13287-016-0377-1, PMID: 27526687 PMC4986362
  89. 89 VaupelPMulthoffG. Accomplices of the hypoxic tumor microenvironment compromising antitumor immunity: adenosine, lactate, acidosis, vascular endothelial growth factor, potassium ions, and phosphatidylserine. Front Immunol. (2017) 8:1887. doi: 10.3389/fimmu.2017.01887, PMID: 29312351 PMC5742577
  90. 90 BatistellaEAMiguelAFPNascimentoNLHortaMCRVieiraDSCRiveroERC. Microvascular density analysis and histological parameters of oral cancer progression. Oral Dis. (2024) 30:2110–21. doi: 10.1111/odi.14694, PMID: 37486622
  91. 91 DenizeTFarahSCimadamoreAFlaifelAWaltonESticco-IvinsMAet al.. Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial. Clin Cancer Res. (2022) 28:748–55. doi: 10.1158/1078-0432.CCR-21-3088, PMID: 34921022 PMC8866215
  92. 92 SeeberAKlinglmairGFritzJSteinkohlFZimmerKCAignerFet al.. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci. (2018) 109:1583–91. doi: 10.1111/cas.13560, PMID: 29498788 PMC5980224
  93. 93 ZhouXLiRLaiMLaiC. Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma. Mol Cancer. (2025) 24:121. doi: 10.1186/s12943-025-02315-9, PMID: 40264130 PMC12012986
  94. 94 WiśniowskiTBrydaJDomosudJWątrobaSJ. Extracellular matrix metalloproteinases in pathophysiology, diagnostics and treatment of renal cell carcinoma - current state of knowledge and future perspectives. Ann Agric Environ Med. (2025) 32:27–45. doi: 10.26444/aaem/192555, PMID: 40159733
  95. 95 WuTKHungTWChenYSPanYRHsiehYHTsaiJP. Corosolic acid inhibits metastatic response of human renal cell carcinoma cells by modulating ERK/MMP2 signaling. Environ Toxicol. (2024) 39:857–68. doi: 10.1002/tox.23999, PMID: 37860891
  96. 96 MaGZhangBFuSLuJZhangLShangPet al.. Formin-related protein 1 facilitates proliferation and aggressive phenotype of clear cell renal cell carcinoma through MAPK/MMP2 pathway. Mol Cell Probes. (2023) 71:101921. doi: 10.1016/j.mcp.2023.101921, PMID: 37454877
  97. 97 RajamaniKThirugnanasambandanSSNatesanCSubramaniamSThangavelBAravindanN. Squalene deters drivers of RCC disease progression beyond VHL status. Cell Biol Toxicol. (2021) 37:611–31. doi: 10.1007/s10565-020-09566-w, PMID: 33219891
  98. 98 SantiAKugeratskiFGZanivanS. Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics. (2018) 18:e1700167. doi: 10.1002/pmic.201700167, PMID: 29280568 PMC5900985
  99. 99 YangYFanRZhangBLiuK. COL6A2 in clear cell renal cell carcinoma: a multifaceted driver of tumor progression, immune evasion, and drug sensitivity. J Transl Med. (2025) 23:875. doi: 10.1186/s12967-025-06793-9, PMID: 40770761 PMC12330150
  100. 100 WinklerJAbisoye-OgunniyanAMetcalfKJWerbZ. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. (2020) 11:5120. doi: 10.1038/s41467-020-18794-x, PMID: 33037194 PMC7547708
  101. 101 BhatPTamboliPSircarKKannanK. Spatial distribution of tumor cells in clear cell renal cell carcinoma is associated with metastasis and a matrisome gene expression signature. Cancers (Basel). (2025) 17:249. doi: 10.3390/cancers17020249, PMID: 39858031 PMC11763402
  102. 102 ZhangYWangXGuYLiuTZhaoXChengSet al.. Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells. Proc Natl Acad Sci U.S.A. (2025) 122:e2420005122. doi: 10.1073/pnas.2420005122, PMID: 39847320 PMC11789090
  103. 103 CongXLiXXuKYinLLiangGSunRet al.. HIF-1α/m(6)A/NF-κB/CCL3 axis-mediated immunosurveillance participates in low level benzene-related erythrohematopoietic development toxicity. Environ Int. (2024) 184:108493. doi: 10.1016/j.envint.2024.108493, PMID: 38350257
  104. 104 Silva PaivaRGomesICasimiroSFernandesICostaL. c-Met expression in renal cell carcinoma with bone metastases. J Bone Oncol. (2020) 25:100315. doi: 10.1016/j.jbo.2020.100315, PMID: 33024658 PMC7527574
  105. 105 FordeAJKolterJZwickyPBaaschSLohrmannFEckertMet al.. Metabolic rewiring tunes dermal macrophages in staphylococcal skin infection. Sci Immunol. (2023) 8:eadg3517. doi: 10.1126/sciimmunol.adg3517, PMID: 37566679
  106. 106 HirschLFlippotREscudierBAlbigesL. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. (2020) 80:1169–81. doi: 10.1007/s40265-020-01327-7, PMID: 32601914
  107. 107 Díaz-MonteroCMRiniBIFinkeJH. The immunology of renal cell carcinoma. Nat Rev Nephrol. (2020) 16:721–35. doi: 10.1038/s41581-020-0316-3, PMID: 32733094
  108. 108 GrobbenY. Targeting amino acid-metabolizing enzymes for cancer immunotherapy. Front Immunol. (2024) 15:1440269. doi: 10.3389/fimmu.2024.1440269, PMID: 39211039 PMC11359565
  109. 109 KumariASyedaSRawatKKumariRShrivastavaA. Melatonin modulates L-arginine metabolism in tumor-associated macrophages by targeting arginase 1 in lymphoma. Naunyn Schmiedebergs Arch Pharmacol. (2024) 397:1163–79. doi: 10.1007/s00210-023-02676-2, PMID: 37639022
  110. 110 LiJZhangQGuanYLiaoDJiangDXiongHet al.. Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. Cell Death Dis. (2022) 13:443. doi: 10.1038/s41419-022-04863-0, PMID: 35525866 PMC9079058
  111. 111 XinXLiZYanXLiuTLiZChenZet al.. Hepatocyte-specific Smad4 deficiency inhibits hepatocarcinogenesis by promoting CXCL10/CXCR3-dependent CD8(+)- T cell-mediated anti-tumor immunity. Theranostics. (2024) 14:5853–68. doi: 10.7150/thno.97276, PMID: 39346534 PMC11426237
  112. 112 ZhuRYeXLuXXiaoLYuanMZhaoHet al.. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. (2025) 37:361–376.e367. doi: 10.1016/j.cmet.2024.10.015, PMID: 39561764
  113. 113 MaZYangJJiaWLiLLiYHuJet al.. Histone lactylation-driven B7-H3 expression promotes tumor immune evasion. Theranostics. (2025) 15:2338–59. doi: 10.7150/thno.105947, PMID: 39990209 PMC11840737
  114. 114 ZhangYHuangYHongYLinZZhaJZhuYet al.. Lactate acid promotes PD-1(+) Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia. Int Immunopharmacol. (2024) 130:111765. doi: 10.1016/j.intimp.2024.111765, PMID: 38447414
  115. 115 JinXZhangNYanTWeiJHaoLSunCet al.. Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential. Front Immunol. (2025) 16:1573039. doi: 10.3389/fimmu.2025.1573039, PMID: 40433363 PMC12106438
  116. 116 LiuYZhouYZhangJLiJZouL. Regulation of CD4 + T cell differentiation and function by glucose metabolism. Genes Immun. (2025) 26:287–96. doi: 10.1038/s41435-025-00340-8, PMID: 40617972
  117. 117 MierJW. The tumor microenvironment in renal cell cancer. Curr Opin Oncol. (2019) 31:194–9. doi: 10.1097/CCO.0000000000000512, PMID: 30985497 PMC6467495
  118. 118 CalvoEBoniVDumasOShinSJRosenSDChaudhryAet al.. Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial. J Immunother Cancer. (2025) 13:e010777. doi: 10.1136/jitc-2024-010777, PMID: 40759440 PMC12323519
  119. 119 De Vries-BrillandMHamilouZGhoshSHengDYCWoodLABasappaNSet al.. Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell Carcinoma. Oncologist. (2025) 4:oyaf240. doi: 10.1093/oncolo/oyaf240, PMID: 40757924 PMC12445671
  120. 120 HuangTPengYLiuRMaBChenJWeiWet al.. Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. Int Immunopharmacol. (2024) 142:113106. doi: 10.1016/j.intimp.2024.113106, PMID: 39288623
  121. 121 JinWYangQChiHWeiKZhangPZhaoGet al.. Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers. Front Immunol. (2022) 13:1025330. doi: 10.3389/fimmu.2022.1025330, PMID: 36532083 PMC9751999
  122. 122 JahangirMYazdaniOKahriziMSSoltanzadehSJavididashtbayazHMivefroshanAet al.. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell Int. (2022) 22:401. doi: 10.1186/s12935-022-02816-3, PMID: 36510217 PMC9743549
  123. 123 Kammerer-JacquetSFDeleuzeASaoutJMathieuRLaguerreBVerhoestGet al.. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int J Mol Sci. (2019) 20:1692. doi: 10.3390/ijms20071692, PMID: 30987368 PMC6480014
  124. 124 StenzelPJSchindeldeckerMTagschererKEFoerschSHerpelEHohenfellnerMet al.. Prognostic and predictive value of tumor-infiltrating leukocytes and of immune checkpoint molecules PD1 and PDL1 in clear cell renal cell carcinoma. Transl Oncol. (2020) 13:336–45. doi: 10.1016/j.tranon.2019.11.002, PMID: 31881506 PMC7031108
  125. 125 HorzumUYanikHTaskiranEZEsendagliG. Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion. Immunology. (2022) 167:640–50. doi: 10.1111/imm.13560, PMID: 36053975
  126. 126 WangQXieBLiuSShiYTaoYXiaoDet al.. What happens to the immune microenvironment after PD-1 inhibitor therapy? Front Immunol. (2021) 12:773168. doi: 10.3389/fimmu.2021.773168, PMID: 35003090 PMC8733588
  127. 127 van DuijnAWillemsenKJvan UdenNOPHoyngLEradesSKosterJet al.. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma. Cancer Immunol Immunother. (2022) 71:529–40. doi: 10.1007/s00262-021-03007-1, PMID: 34268602 PMC8854324
  128. 128 TziakouPTheodoropoulosGTsiambasEZizi-SermpetzoglouAPeschosDMastronikoliSet al.. Impact of PD-L1 protein expression on renal cell carcinoma histo-differentiation. Anticancer Res. (2021) 41:3809–13. doi: 10.21873/anticanres.15173, PMID: 34281840
  129. 129 ChenSCrabillGAPritchardTSMcMillerTLWeiPPardollDMet al.. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. (2019) 7:305. doi: 10.1186/s40425-019-0770-2, PMID: 31730010 PMC6858680
  130. 130 GuoJNChenDDengSHHuangJRSongJXLiXYet al.. Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer. Cancer Immunol Immunother. (2022) 71:1313–30. doi: 10.1007/s00262-021-03076-2, PMID: 34657172 PMC9122887
  131. 131 HolderAMDedeiliaASierra-DavidsonKCohenSLiuDParikhAet al.. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. (2024) 24:498–512. doi: 10.1038/s41568-024-00705-7, PMID: 38867074
  132. 132 HuZLeetDEAllesøeRLOliveiraGLiSLuomaAMet al.. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. (2021) 27:515–25. doi: 10.1038/s41591-020-01206-4, PMID: 33479501 PMC8273876
  133. 133 ChenHLiZQiuLDongXChenGShiYet al.. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J Immunother Cancer. (2022) 10:e004389. doi: 10.1136/jitc-2021-004389, PMID: 36113894 PMC9486396
  134. 134 LeeMSamsteinRMValeroCChanTAMorrisLGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccin Immunother. (2020) 16:112–5. doi: 10.1080/21645515.2019.1631136, PMID: 31361563 PMC7012182
  135. 135 TurajlicSLitchfieldKXuHRosenthalRMcGranahanNReadingJLet al.. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. (2017) 18:1009–21. doi: 10.1016/S1470-2045(17)30516-8, PMID: 28694034
  136. 136 ClarkDJDhanasekaranSMPetraliaFPanJSongXHuYet al.. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. (2019) 179:964–983.e931. doi: 10.1016/j.cell.2019.10.007, PMID: 31675502 PMC7331093
  137. 137 MessaiYGadSNomanMZLe TeuffGCouveSJanjiBet al.. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von hippel-lindau gene mutation status. Eur Urol. (2016) 70:623–32. doi: 10.1016/j.eururo.2015.11.029, PMID: 26707870
  138. 138 MiaoDMargolisCAGaoWVossMHLiWMartiniDJet al.. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. (2018) 359:801–6. doi: 10.1126/science.aan5951, PMID: 29301960 PMC6035749
  139. 139 BraunDAIshiiYWalshAMVan AllenEMWuCJShuklaSAet al.. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. (2019) 5:1631–3. doi: 10.1001/jamaoncol.2019.3158, PMID: 31486842 PMC6735411
  140. 140 da CostaWHRezendeMCarneiroFCRochaRMda CunhaIWCarraroDMet al.. Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int. (2014) 113:E157–163. doi: 10.1111/bju.12426, PMID: 24053427
  141. 141 MaxwellMBHom-TedlaMSYiJLiSRiveraSAYuJet al.. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. (2024) 187:3390–3408.e3319. doi: 10.1016/j.cell.2024.04.025, PMID: 38754421 PMC11193641
  142. 142 MondalIDasOSunRGaoJYuBDiazAet al.. PP2Ac deficiency enhances tumor immunogenicity by activating STING-type I interferon signaling in glioblastoma. Cancer Res. (2023) 83:2527–42. doi: 10.1158/0008-5472.CAN-22-3382, PMID: 37219874 PMC10525036
  143. 143 BraunDAHouYBakounyZFicialMSant’ AngeloMFormanJet al.. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. (2020) 26:909–18. doi: 10.1038/s41591-020-0839-y, PMID: 32472114 PMC7499153
  144. 144 LiBELiGYCaiWZhuQSeruggiaDFujiwaraYet al.. In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice. Blood Adv. (2023) 7:5281–93. doi: 10.1182/bloodadvances.2022009455, PMID: 37428871 PMC10506108
  145. 145 BenitezJCRecondoGRassyEMezquitaL. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Q J Nucl Med Mol Imaging. (2020) 64:162–74. doi: 10.23736/S1824-4785.20.03250-1, PMID: 32107903
  146. 146 LuLLeiYLiYWangL. LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration. Aging (Albany NY). (2024) 16:1484–95. doi: 10.18632/aging.205440, PMID: 38226972 PMC10866424
  147. 147 YangLLiuYZhangBYuMHuangFZengJet al.. CEACAM1 is a prognostic biomarker and correlated with immune cell infiltration in clear cell renal cell carcinoma. Dis Markers. (2023) 2023:3606362. doi: 10.1155/2023/3606362, PMID: 36712923 PMC9876685
  148. 148 KlümperNRalserDJZarblRSchlackKSchraderAJRehlinghausMet al.. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. (2021) 9:e002949. doi: 10.1136/jitc-2021-002949, PMID: 34446578 PMC8395367
  149. 149 RoyAMGeorgeS. Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena. Cancer Drug Resist. (2023) 6:642–55. doi: 10.20517/cdr.2023.47, PMID: 37842239 PMC10571056
  150. 150 GrimmMOEstebanEBarthélémyPSchmidingerMBuschJValderramaBPet al.. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. (2023) 24:1252–65. doi: 10.1016/S1470-2045(23)00449-7, PMID: 37844597
  151. 151 SchoenfeldDADjureinovicDSuDGZhangLLuBYKamgaLet al.. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight. (2024) 10:e184545. doi: 10.1172/jci.insight.184545, PMID: 39561007 PMC11721305
  152. 152 BergmannLAlbigesLAhrensMGross-GoupilMBoletiEGravisGet al.. Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Ann Oncol. (2025) 36:796–806. doi: 10.1016/j.annonc.2025.03.016, PMID: 40180121
  153. 153 TakamatsuKTanakaNHakozakiKTakahashiRTeranishiYMurakamiTet al.. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals Malignancy. Nat Commun. (2021) 12:5547. doi: 10.1038/s41467-021-25865-0, PMID: 34545095 PMC8452744
  154. 154 LinCCGarraldaESchöffskiPHongDSSiuLLMartinMet al.. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid Malignancies. Oncoimmunology. (2024) 13:2290787. doi: 10.1080/2162402X.2023.2290787, PMID: 38170160 PMC10761073
  155. 155 TopalianSLDrakeCGPardollDM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. (2015) 27:450–61. doi: 10.1016/j.ccell.2015.03.001, PMID: 25858804 PMC4400238
  156. 156 WangKCoutifarisPBrocksDWangGAzarTSolisSet al.. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells. Cancer Cell. (2024) 42:1582–1597.e1510. doi: 10.1016/j.ccell.2024.08.007, PMID: 39214097 PMC11387127
  157. 157 MotzerRJTannirNMMcDermottDFArén FronteraOMelicharBChoueiriTKet al.. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. (2018) 378:1277–90. doi: 10.1056/NEJMoa1712126, PMID: 29562145 PMC5972549
  158. 158 TianLGoldsteinAWangHChing LoHSun KimIWelteTet al.. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. (2017) 544:250–4. doi: 10.1038/nature21724, PMID: 28371798 PMC5788037
  159. 159 RiniBIPlimackERStusVGafanovRHawkinsRNosovDet al.. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. (2019) 380:1116–27. doi: 10.1056/NEJMoa1816714, PMID: 30779529
  160. 160 MotzerRJPenkovKHaanenJRiniBAlbigesLCampbellMTet al.. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. (2019) 380:1103–15. doi: 10.1056/NEJMoa1816047, PMID: 30779531 PMC6716603
  161. 161 DrakeCGSteinMN. The immunobiology of kidney cancer. J Clin Oncol. (2018) 29:Jco2018792648. doi: 10.1200/JCO.2018.79.2648, PMID: 30372396
  162. 162 WangLCLoASchollerJSunJMajumdarRSKapoorVet al.. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. (2014) 2:154–66. doi: 10.1158/2326-6066.CIR-13-0027, PMID: 24778279 PMC4007316
  163. 163 SantagataSNapolitanoMD’AlterioCDesicatoSMaroSDMarinelliLet al.. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget. (2017) 8:77110–20. doi: 10.18632/oncotarget.20363, PMID: 29100374 PMC5652768
  164. 164 WetterstenHIAboudOALaraPNJr.WeissRH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. (2017) 13:410–9. doi: 10.1038/nrneph.2017.59, PMID: 28480903
  165. 165 RiesenbergRWeilerCSpringOEderMBuchnerAPoppTet al.. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res. (2007) 13:6993–7002. doi: 10.1158/1078-0432.CCR-07-0942, PMID: 18056175
  166. 166 LaraPNJr.VillanuevaLIbanezCErmanMLeeJLHeinrichDet al.. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). BMC Cancer. (2024) 23:1253. doi: 10.1186/s12885-023-10971-7, PMID: 39054430 PMC11270760
  167. 167 LongGVDummerRHamidOGajewskiTFCaglevicCDalleSet al.. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. (2019) 20:1083–97. doi: 10.1016/S1470-2045(19)30274-8, PMID: 31221619
  168. 168 GienLTEnserroDMBlockMSWaggonerSDuskaLRWahner-HendricksonAEet al.. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. (2024) 186:61–8. doi: 10.1016/j.ygyno.2024.03.027, PMID: 38603953 PMC11265792
  169. 169 NguyenCBOhEBaharPVaishampayanUNElseTAlvaAS. Novel approaches with HIF-2α Targeted therapies in metastatic renal cell carcinoma. Cancers (Basel). (2024) 16:601. doi: 10.3390/cancers16030601, PMID: 38339352 PMC10854987
  170. 170 Meric-BernstamFTannirNMIliopoulosOLeeRJTelliMLFanACet al.. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin Cancer Res. (2022) 28:1540–8. doi: 10.1158/1078-0432.CCR-21-2972, PMID: 35140121 PMC9164172
  171. 171 MouWDengZZhuLJiangALinAXuLet al.. Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma. Sci Adv. (2025) 11:eadu1727. doi: 10.1126/sciadv.adu1727, PMID: 40203108 PMC11980860
  172. 172 ZarrabiKKLanadeOGeynismanDM. Determining front-line therapeutic strategy for metastatic clear cell renal cell carcinoma. Cancers (Basel). (2022) 14:4607. doi: 10.3390/cancers14194607, PMID: 36230530 PMC9559659
  173. 173 Nguyen DucAHeinzmannDBergeCWolbersM. A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies. Pharm Stat. (2021) 20:202–11. doi: 10.1002/pst.2066, PMID: 32869509
  174. 174 BraunDAMoranzoniGCheaVMcGregorBABlassETuCRet al.. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. (2025) 639:474–82. doi: 10.1038/s41586-024-08507-5, PMID: 39910301 PMC11903305
  175. 175 Barragan-CarrilloRSaadESalibyRMSunMAlbigesLBexAet al.. First and second-line treatments in metastatic renal cell carcinoma. Eur Urol. (2025) 87:143–54. doi: 10.1016/j.eururo.2024.10.019, PMID: 39505582
  176. 176 O’ConnellBCHubbardCZizlspergerNFitzgeraldDKutokJLVarnerJet al.. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. (2024) 12:e009160. doi: 10.1136/jitc-2024-009160, PMID: 39214650 PMC11367338
  177. 177 MotzerRJSchmidingerMEtoMSuarezCFiglinRLiuYet al.. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. (2023) 19:113–21. doi: 10.2217/fon-2022-0802, PMID: 36752726 PMC13248041
  178. 178 ZhangYChenJLiuHDaiJZhaoJZhuSet al.. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Cancer Treat Rev. (2024) 129:102787. doi: 10.1016/j.ctrv.2024.102787, PMID: 38905806
  179. 179 WashinoSShirotakeSTakeshitaHInoueMMiuraYHyodoYet al.. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. Int J Clin Oncol. (2023) 28:1651–8. doi: 10.1007/s10147-023-02406-x, PMID: 37658926

Author Contributions

  • Olivier Dubois: Visualization, Writing – original draft, Validation, Methodology
  • Margot Dubois: Supervision

Declarations

Funding

This study received no specific funding.

Data Availability

Demonstration content: the full text of this article is adapted from “Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma” by Wen and colleagues (Frontiers in Immunology, 2025; https://doi.org/10.3389/fimmu.2025.1643533), which is available under a Creative Commons license (https://creativecommons.org/licenses/by/4.0/).

Ethics Statement

No ethics approval was required for this study.

Declaration of Generative AI Use

A language model was used to check the grammar of the abstract. No content was generated.

Download
PDFJATS XML